Peptide News Digest

GLP-1 Weight Regain Trial, Fewer Falls on GLP-1s in Veterans, Melanotan II Melanoma Case, Nectin-4 Peptide PET Scan

Meals or an app slowed regain after people stopped GLP-1s, GLP-1s tracked with fewer falls in veterans, and a Melanotan II user got a new melanoma.

8 stories · Covering research, clinical-trials

Editor's Note

Thursday's research asked what happens around GLP-1 treatment rather than during it. A small Tufts and UT Southwestern trial found that delivered meals or a wellness app cut weight regain in the four months after people stopped the drugs, and Viking started a trial of lower-intensity maintenance doses for its own drug. Two large record studies linked GLP-1 drugs with fewer falls in veterans and fewer cases of kidney failure than finerenone, but both are observational, and the kidney study found no clear difference in absolute risk. A Michigan cost model found both semaglutide and sleeve surgery worth their price for older adults with heart disease, with surgery slightly ahead. Outside the incretin drugs, a case report described a man who developed a new melanoma weeks after injecting Melanotan II bought at a gym, and two Chinese teams showed peptide tracers that light up breast and other tumors on PET scans, one already tested in six patients.

Research

Delivered Meals or a Wellness App Cut Weight Regain by About 7 Points in the Four Months After Stopping GLP-1 Drugs, Pilot Trial Finds

Researchers at Tufts University and UT Southwestern reported in Obesity Science & Practice on October 7, 2026 a pilot randomized trial of 39 adults who had lost weight on GLP-1 drugs and were stopping them, assigned to usual care (14), a digital wellness app (12), or medically tailored meals (13). Over the first four months off the drug, both the app and meal groups gained less weight than the control group, by 7.16 and 7.17 percentage points of body weight. Weight was an exploratory outcome, measured with Bluetooth scales at home, and the authors said larger and longer trials are needed.

#glp-1 #weight-regain #discontinuation #nutrition
Research

Veterans Starting GLP-1 Drugs Had 13% Fewer Falls and Slightly Slower Frailty Than Those Starting DPP-4 Inhibitors, VA Study Finds

A UT Southwestern study published October 7, 2026 in Diabetes, Obesity and Metabolism compared 73,592 matched pairs of veterans with type 2 diabetes who started a GLP-1 drug or a DPP-4 inhibitor, an older diabetes pill, between 2006 and 2021. Over about 27 months, the GLP-1 group had a 13% lower fall rate (incidence rate ratio 0.87) and slightly less worsening on a frailty index. The link weakened in people who were already severely frail, and the observational design cannot prove the drugs caused the difference.

#glp-1 #frailty #type-2-diabetes #veterans #real-world-evidence
Research

GLP-1 Drugs and Tirzepatide Linked to 29% Lower Relative Risk of Kidney Failure Than Finerenone, but No Clear Absolute Difference, in TriNetX Study

Researchers at Hebrew University and Hadassah Medical Center reported in Diabetes, Obesity and Metabolism on October 7, 2026 a records study of 4,554 matched adults with type 2 diabetes and stage 3 or 4 chronic kidney disease who started a GLP-1 drug or tirzepatide, or finerenone, a non-steroidal kidney drug. Kidney failure or dialysis occurred in 4.8% versus 6.0% within 2.5 years (hazard ratio 0.71), but the absolute risk difference of 1.14 percentage points was not statistically clear. Albuminuria, a key kidney measure, was missing for most people, so the authors warned of residual confounding.

#glp-1 #tirzepatide #kidney-disease #finerenone #real-world-evidence
Research

Michigan Model Finds Semaglutide and Sleeve Gastrectomy Both Cost-Effective for Older Adults With Obesity and Heart Disease, With Surgery Slightly Ahead

A University of Michigan simulation published October 7, 2026 in Obesity modeled Black and White adults aged 65 to 70 with a BMI of 35 or higher and cardiovascular disease over 25 years. Compared with no treatment, semaglutide 2.4 mg cost $7,300 and sleeve gastrectomy $12,100 per quality-adjusted life year gained, and surgery cost $53,700 per extra quality-adjusted year compared with semaglutide, within the model's $100,000 threshold. Surgery was the most cost-effective option in 57% of simulations; semaglutide was slightly more equitable between the two groups but not enough to change the ranking.

#semaglutide #bariatric-surgery #cost-effectiveness #health-equity
Clinical Trials

Viking Starts Part 2 of Its VK2735 Maintenance Trial, Testing Oral and Less Frequent Injected Doses in About 195 Adults

Viking Therapeutics said on October 6, 2026 that it had started Part 2 of its maintenance study of VK2735, its GLP-1 and GIP dual agonist. About 195 adults with obesity who took weekly VK2735 injections or placebo for 21 weeks in Part 1 are being randomized to daily or weekly oral doses, monthly or every-other-week injections, or placebo through week 33, with safety, tolerability, and drug levels as the main goals and weight change as an exploratory measure. Viking expects results in 2027; its two Phase 3 VANQUISH trials, with about 4,500 and 1,000 participants, are fully enrolled.

#vk2735 #viking-therapeutics #weight-regain #oral-peptide
Research

Case Report: Man Develops New Melanoma Weeks After Injecting Melanotan II Bought at a Gym

Doctors in Illinois and Michigan described in JAAD Case Reports a 46-year-old man with a history of melanoma who began daily injections of Melanotan II, an unapproved tanning peptide, bought at a local gym, Gizmodo reported on October 8, 2026. About five weeks later he noticed moles changing size, shape, and color and stopped; a biopsy about a month after that confirmed an early-stage melanoma. He also used tanning beds two to three times a week and had taken anabolic steroids, so the authors could not rule out other causes, and they warned about unregulated peptides promoted on social media.

#melanotan-ii #melanoma #gray-market #case-report
Research

Soochow University's Nectin-4 Cyclic Peptide PET Tracer Matches FDG Scans and Finds More Bone and Liver Spread in Six Breast Cancer Patients

Researchers at the First Affiliated Hospital of Soochow University in China reported in the Journal of Nuclear Medicine on October 8, 2026 a gallium-68 tracer built on a dimeric (two-unit) cyclic peptide, [68Ga]Ga-TDN1, that binds nectin-4, a tumor protein also targeted by the antibody-drug conjugate enfortumab vedotin (Padcev). After animal tests showed specific tumor uptake, a first-in-human pilot in six breast cancer patients found it performed comparably to standard FDG PET for primary tumors and lymph nodes and detected bone and liver metastases better. The tracer was well tolerated; the human study is very small.

#peptide-imaging #cyclic-peptide #breast-cancer #nectin-4
Research

Fujian Team Uses AI to Design TR23, a TROP-2-Targeting Peptide PET Tracer, Tested in Three Mouse Tumor Models

Researchers at Fujian Medical University reported in Bioconjugate Chemistry on October 8, 2026 that they used the PepMimic AI platform to design TR23, a peptide designed by mimicking a protein binding interface, and labeled it with gallium-68 for PET imaging. The tracer bound TROP-2, a protein common in many solid tumors and the target of the antibody-drug conjugate Trodelvy, with nanomolar strength, and gave clear, specific tumor signals in pancreatic, prostate, and thyroid cancer models in mice, with signal strength tracking TROP-2 levels in tissue. The work is preclinical.

#peptide-imaging #ai-drug-design #trop-2 #preclinical

Related Guides